DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c576bc/the_state_of_bioma) has announced the addition of the "The State of Biomarkers in Clinical Development" report to their offering.
This innovative report focuses on interviews with 44 biomarkers specialists from 37 different biopharma companies. Participants provide views to their biomarkers strategies, experiences and predictions for their adoption in drug development. Specifically, the report details pharma companies, current and future adoption of 6 different types of biomarkers including: Diagnostic Biomarkers, Early Detection / Screening Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Surrogate Biomarkers and Toxicity Biomarkers.
The report also reveals pharma companies; current and future adoption of many specific biomarkers technologies including: Bioinformatics and Systems Biology, Genomics, Glycomics, Histomics, Imaging, Metabolomics, and Proteomics. Further, this research uncovers the proportion of products within respondents pipelines that contain biomarker strategies and the stages at which biomarker strategies are developed for products. Respondents also discuss their development strategies for products with biomarkers.
Key Topics Covered:
- The State of Biomarkers
- Copyright and Usage Guidelines
- Introduction
- Study Findings
- Maturing service identifies benefits of early strategy
- Traditional adoption curve -future industry status
- Outsourcing strategies
- Outsourcing of biomarker identification and studies
- Biomarkers as a point of differentiation
- Sponsor drivers and roadblocks
- Roadblocks for biomarker development
- Trends in biomarker types and technologies
- Current and future use of biomarkers types
- Current and future use of biomarkers technologies
- Appendix of Charts and Graphs
- Biomarker Adoption
- Traditional adoption curve -current company status
- Traditional adoption curve -future industry status
- Biomarker usage
- Most suitable compound type for biomarkers
- Current and best time to evaluate biomarkers
- Current and future portfolio with biomarkers
- Outsourcing penetration
- Service provider strategies
- Invest in IP
- Outsourcing of biomarker identification
- Outsourcing of a study with a biomarker
- Propensity to outsource a study with a biomarker
- Biomarker ID as pull-through for clinical studies
- Credible biomarker offering
- Preferred service provider for biomarkers
- Service provider differentiation ideas
- Pharma's Internal Drivers and Capabilities
- Drivers for biomarker development
- Roadblocks for biomarker development
- Current use of biomarkers types
- Future use of biomarkers types
- Current use of biomarkers technologies
- Future use of biomarkers technologies
- Respondent Characteristics
- Decision-making areas of responsibility
- Decision-making Phase of responsibility
- Biomarker-Companion diagnostic responsibility
- Job title
- Company type
- Company size
- Respondent and Corporate Headquarters location
- Therapeutic area responsibility
Companies Mentioned:
- Covance
- Quintiles
- ICON
- PPD
- Biomedical Systems DCRI - DUKE PAREXEL
- Bioclinica
- US Oncology
- AAI
- Clearstone (x-MDS)
- CareFusion(Cardinal) CEDRA
- Cetero
- Clinsys
- Esoterix
- Expression Analysis
- i3 Pharma Services
- Kendle
- MedPace
- Omnicare
- Pacific Biomarkers
- PRA
- Spectra
For more information visit http://www.researchandmarkets.com/research/c576bc/the_state_of_bioma